All In Biotech

Drug Trial Radar · NCT07297979

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Xaluritamig in Adult, Adolescent and Pediatric Participants With Relapsed or Refractory Ewing Sarcoma

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Apr 8, 2026

Primary completion

May 26, 2030

Study completion May 26, 2030

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Dec 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric participants with relapsed or refractory EWS.

Conditions

  • Ewing Sarcoma

Interventions

  • XaluritamigDrug

    Participants will receive xaluritamig via short-term intravenous (IV) infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing a Dose-limiting Toxicity (DLT) (Part 1 Only)Time frame: Up to 42 days
  2. Number of Participants with Treatment-emergent Adverse EventsTime frame: Up to approximately 2.5 years

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • University of California Los Angeles

    Los Angeles, California · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • C.S. Mott Children's Hospital

    Ann Arbor, Michigan · Recruiting

  • Mayo Clinic Childrens Center

    Rochester, Minnesota · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center Childrens Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Chris OBrien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Perth Childrens Hospital

    Nedlands, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.